The types classification within Custom Peptide CDMO Services segmentation differentiates services by the nature of the peptide product: linear peptides, cyclic peptides, and modified peptides (including stapled, PEGylated, and non‑natural amino‑acid variants). Linear peptides, the most common format, capture roughly 45% of service contracts because they are foundational to both drug discovery and diagnostic workflows. Cyclic peptides, contributing about 35%, are sought after for their enhanced stability and bioavailability, driving specialized synthesis routes and conformational control. Modified peptides, which hold the remaining 20%, involve complex chemistries such as backbone cyclization, side‑chain protection strategies, and incorporation of exotic residues, demanding advanced process development and analytical capabilities. The revenue distribution mirrors the technical complexity: linear peptide projects generate steady cash flow due to high volume; cyclic peptide services command premium pricing linked to higher R&D risk; and modified peptide contracts, though fewer, yield the highest margin per unit owing to the specialized expertise required.